Ir-based HDR-BT studies have demonstrated low toxicity but inferior 6-year biochemical free survival rates to conventional regimens (82% vs 95%). RSBT may make the single-shot regimen a more durable therapy via dose escalation without adding toxicity. RSBT could also be used to deliver single-shot boosts to external beam radiotherapy with lower toxicity than conventional HDR-BT through urethral sparing. Materials/Methods: A fully automated RSBT delivery system is presented that uses a compact six degrees-of-freedom robot to align and connect a shield control assembly to each implanted needle in series under accurate optical guidance. Following connection to a needle, the shield control assembly uses rotational motors to drive a flexible, partially-shielded catheter containing a conventional afterloader-controlled 27 Ci 169 Yb source down the needle in a helical manner. Functional components critical to catheter control and system guidance are redundant to ensure safety in case of individual component malfunction. Intensity modulation is achieved through control of the angular velocity of the shielded catheter, and there is no possibility for inter-needle interference given only one shield is inside the patient at once. Treatment plans for 26 patients were created for plan goals of either dose escalation or urethral sparing, for both 192 Ir-based HDR-BT and 169 Yb-based RSBT. Needle placement was manually optimized. The prescription for the dose escalation plan was 20.5 Gy in 1 fraction and for the urethral sparing plan was 15 Gy in 1 fraction. Dose was prescribed such that 90% of the planning target volume (PTV) received 110% of the prescription dose. Results: For dose escalation, with equivalent urethra D 10%, RSBT increased the PTV D 90% to 29.5 AE 0.9 Gy (average AE standard deviation) from the HDR-BT PTV D 90% of 22.5 AE 0.0 Gy, an improvement of 30.9% AE 4.1% . Corresponding treatment times were 50.3 AE 6.2 minutes for RSBT and 15.4 AE 2.1 minutes for HDR-BT. For urethra sparing, with equivalent PTV D 90% , RSBT decreased the urethra D 10% to 12.1 AE 0.5 Gy from the HDR-BT urethra D 10% of 15.9 AE 0.4 Gy, a reduction of 24.1% AE 3.3%. Corresponding treatment times were 29.3 AE 3.7 minutes for RSBT and 11.8 AE 1.7 minutes for HDR-BT. Conclusion: The 169Yb-based RSBT can increase PTV D 90%, without exceeding normal tissue constraints, or decrease urethral D 10% relative to HDR-BT with treatment times of less than one hour. The delivery system uses a single source and could provide an effective single-shot treatment option for prostate cancer as a monotherapy or as a boost to external beam radiotherapy. An optically-guided, robotic, helical RSBT system could provide automated, efficient, and safe delivery.
Purpose/Objective(s): To develop a complete set of rotatable applicator system for intensity modulated brachytherapy (IMBT) of advanced cervical cancers, and to install them in a brachytherapy treatment room. Materials/Methods: Recently, we developed a novel tandem applicator with a rotatable internal shield for IMBT. However, a complete set of applicator system is required to treat a patient with advanced cervical tumor, which consists of IMBT tandem applicator, coupling structure between IMBT tandem and conventional ovoids, their leveling device, rotation system of IMBT tandem (including mini DC-motor, motor adaptor, motor controller, and interfacing software), mechanical channel conversion adaptor, semi-automatic beam delivery system, dummy IMBT tandem, applicator clamping device, QA system of IMBT tandem, Pelvic immobilizer etc. In addition, a safe and reliable treatment workflow and protocol should be established. Results: Most of the listed instruments has been developed, and their performance was tested for IMBT. Especially, the QA system of IMBT tandem could check dosimetrically the coincidence between reading and real angles on daily base. The semi-automatic beam delivery system was also tested safely by using a check cable instead of Ir-192 source. We confirmed that the check cable could be loaded into the IMBT tandem sequentially after rotating the shield to a required angle for treatment. All of the developed instruments were installed after the performance test (Table 1) , and a treatment workflow was designed on the basis of current workflow. Conclusion: We developed a complete set of rotatable applicator system for IMBT of advanced cervical cancers, and installed them in our brachytherapy treatment room after their successful performance test. The entire system will be tested comprehensively soon.
